Recently, outstanding clinical results have demonstrated the power of the immune system to eradicate cancer. However current cancer immunotherapy using immune checkpoint (IC) inhibitors has cured only a minority of patients The frequent failure of cancer immunotherapy to cure patients has been attributed to the lack of tumor-specific CD8+ T cells and/or IC expression at the tumor site and to the immunosuppressive tumor microenvironment